Ken Laderman joined Sydnexis as Vice President of Manufacturing and CMC in 2022. Ken led the completion of the clinical and registration drug product manufacturing and the completion of the CMC portions of the NDA for SYD-101. Prior to his role at Sydnexis, was the Vice President of Manufacturing at AgBiome. At AgBiome, Ken was responsible for increasing the product inventory for launch by 3400% and reducing COGs by 84%. Prior to AgBiome, Ken directed the manufacturing of the API for the only biologic in the Bausch & Lomb drug portfolio. Before Bausch& Lomb, Ken was head of process development and cGMP manufacturing for the Center for Biomedicine and Genetics at the City of Hope. Ken holds a B.A. in Biology and History from Pomona\ College and a Ph.D. in Biology from The Johns Hopkins University, with post-doctoral work at The California Institute of Technology and UCLA. His doctoral research focused on the relationship between structure and function in hyperthermophilic proteins.